[Long-term experiences with autoinjection therapy of papaverine in erectile dysfunction].
Long-term experience with intracavernous self-injection of papaverine in 36 patients with erectile failure is reported. The average required dose of papaverine in 2037 documented injections was 31.5 mg. The rate of complications was low with a mean follow-up of 6.9 months. Prolonged erections occurred four times. Two patients reported the development of tolerance. In one man circumscribed induration of the tunica albuginea was observed, which disappeared spontaneously after change of the injection site. No infections of the corpora cavernosa, circulatory disturbances or signs of hepatotoxicity were observed.
Jantos
C
C
Arbeitsgruppe Erektile Dysfunktion Giessen-Marburg.
Krause
W
W
Kauss
E
E
Weidner
W
W
D000328:Adult; D000368:Aged; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage* / Q000009:adverse effects; D010410:Penile Erection / Q000187:drug effects*; D010413:Penis / Q000098:blood supply; D012039:Regional Blood Flow / Q000187:drug effects; D012646:Self Administration
D010208:Papaverine
Langzeiterfahrungen mit der Autoinjektionstherapie von Papaverin bei erektiler Dysfunktion.